ArticleJournal of clinical laboratory analysis2007
Hypercomplementemia in adult patients with IgA nephropathy.
Article in Journal of clinical laboratory analysis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- A Rare Genetic Defect ofFrontiers in immunology · 2019Trial
- Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression.Clinical and experimental immunology · 2015Trial
- Renal-Limited Thrombotic Microangiopathy in Infants: A Case Series.Kidney medicine · 2026Article
- Research progress on the lectin pathway of complement in IgA nephropathy.Frontiers in immunology · 2026Review
- Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy.International urology and nephrology · 2022Article
- Functional variant rs12614 inFrontiers in immunology · 2022Article
- The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?Journal of clinical medicine · 2021Review
- The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?Pediatric nephrology (Berlin, Germany) · 2019Article
- Serum C3/C4 ratio is a novel predictor of renal prognosis in patients with IgA nephropathy: a retrospective study.Immunologic research · 2018Article
- Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study.BMC nephrology · 2017Article
- What Genetics Tells Us About the Pathogenesis of IgA Nephropathy: The Role of Immune Factors and Infection.Kidney international reports · 2017Review
- The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.Frontiers in immunology · 2016Review
- Current Understanding of the Role of Complement in IgA Nephropathy.Journal of the American Society of Nephrology : JASN · 2015Review
- Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy.Journal of the American Society of Nephrology : JASN · 2015Article
- Implication of urinary complement factor H in the progression of immunoglobulin A nephropathy.PloS one · 2015Article
- Comparative proteomic analysis of renal tissue in IgA nephropathy with iTRAQ quantitative proteomics.Biomedical reports · 2014Article
- Pathological scenario with the mannose-binding lectin in patients with IgA nephropathy.Journal of biomedicine & biotechnology · 2012Review
- Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function.BMC nephrology · 2011Article
- Pathogenetic and therapeutic approaches to IgA nephropathy using a spontaneous animal model, the ddY mouse.Clinical and experimental nephrology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is the most common form of chronic glomerulonephritis. Although glomerular deposition of complement components is well known, the evidence of serological complement activation in IgAN is inconclusive. We hypothesized that serum levels of complement components and regulatory proteins in patients with IgAN are correlated with its pathogenesis. In the present study we measured complement components in 50 patients with IgAN and 50 healthy volunteers. C5, C1 inhibitor, factor B, C4 binding protein, factor H, and factor I were measured with the use of single radial immunodiffusion. Mannose-binding lectin (MBL) and properdin (P) were measured by enzyme-linked immunosorbent assay (ELISA). The correlations among complements in the sera of patients with clinical gradings for IgAN (i.e., the good prognosis group, relatively good prognosis group, relatively poor prognosis group, and poor prognosis group) were evaluated. CH50, C4, factor B, P, factor I, and factor H were significantly higher in IgAN patients than in healthy controls. There were significant correlations between C5 and C4 binding protein, between C3 and C5, or between C4 and factor B in patients with IgAN. In the poor prognosis group, C4 binding protein was significantly higher than in the other groups of IgAN patients. hypercomplementemia occurs in IgAN and is associated with an increase in complement regulatory protein (CRP). C4 binding protein analyses can be used to predict disease prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.